Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials including 31,397 Subjects Worldwide
2025 cumulative-dose meta-analysis (31,397 subjects): low-dose colchicine lowered post-treatment hs-CRP (mean difference approximately -0.40 mg/L) in secondary prevention; the largest cardiovascular benefit is linked to on-treatment hs-CRP falling below roughly 2 mg/L.
Evidence
—
Not Rated
Sample
—
subjects
Duration
—
study period
Journal
American Journal of Cardiovascular Drugs
Aug 2025
Structured Methods
- Study Design
- Meta-analysis
- Sample Size
- Not reported
- Study Duration
- Not reported
- Methodology
- Not reported
- Limitations
- Not reported
Citations & References
Unknown authors (2025). Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials including 31,397 Subjects Worldwide. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-025-00743-y
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
